Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.31 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4105815 | 1.00 | PDE4B (0.43) | PDE4BCHRM3NR3C1MAPK1MMP13 | |
| SCHEMBL4105807 | 1.00 | PDE4B (0.43) | PDE4BCHRM3NR3C1MAPK1MMP13 | |
| SCHEMBL4093801 | 1.00 | PDE4B (0.43) | PDE4BCHRM3NR3C1MAPK1MMP13 | |
| Hydrochloric Acid SCHEMBL4087817 | 0.99 | PDE4B (0.43) | PDE4BCHRM3NR3C1MAPK1MMP13 | |
| Hydrochloric Acid SCHEMBL4087811 | 0.99 | PDE4B (0.43) | PDE4BCHRM3NR3C1MAPK1MMP13 | |
| SCHEMBL1363605 | 0.95 | CHRM3 (0.44) | PDE4BCHRM3 | |
| SCHEMBL1363606 | 0.95 | CHRM3 (0.44) | PDE4BCHRM3 | |
| SCHEMBL4106919 | 0.94 | PDE4B (0.47) | PDE4BCHRM3NR3C1MAPK1MMP13 | |
| SCHEMBL12053634 | 0.94 | PDE4B (0.47) | PDE4BCHRM3NR3C1MAPK1MMP13 | |
| SCHEMBL4106910 | 0.94 | PDE4B (0.47) | PDE4BCHRM3NR3C1MAPK1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084449-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-27 | — | — | US | claimed |
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | claimed |
| US-8084449-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE1A, PDE4B | PDE4B 3/4885CHRM3 8/4885NR3C1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.